---
document_datetime: 2026-02-16 15:36:42
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pregabalin-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pregabalin-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.2669084
conversion_datetime: 2026-02-18 17:43:17.746431
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Pregabalin Zentiva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 13/02/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323074                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other obligations and conditions (e.g. agreed wording + QRD template) - Accepted C.I.11.z - to align the RMP with the approved RMP V14.2 for reference product Lyrica (Last updated on 02/05/2025). The RMP has been updated with the list of safety concerns and pharmacovigilance plan and the removal of specific adverse reaction and follow-up questionnaire for safety concern Abuse.                                                                                                                       |            |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IA / EMA/VR/0000323935 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.4 Deletion of certificates (in case multiple certificates exist per material) - Accepted | 04/02/2026 |